Speedy listing of Iressa's insurance price urged

In a recent meeting with the local Health World Network over the pending health insurance price of Iressa, an anticancer agent, AstraZeneca Korea said that the government is still in the process of assessing its reimbursement price level, which has been delayed for more than two months, noting that it often takes five months between obtaining for licenses for new products to assessment of reimb...